Venus Concept Inc. (NASDAQ:VERO) Short Interest Up 3,094.9% in June

Venus Concept Inc. (NASDAQ:VERO) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 252,400 shares, an increase of 3,094.9% from the May 31st total of 7,900 shares. Based on an average daily trading volume, of 1,413,700 shares, the days-to-cover ratio is currently 0.2 days. Approximately 10.1% of the shares of the company are sold short.

Insiders Place Their Bets

In other Venus Concept news, major shareholder Michael Willingham Masters sold 102,717 shares of Venus Concept stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $1.20, for a total value of $123,260.40. Following the completion of the transaction, the insider now directly owns 383,345 shares of the company’s stock, valued at approximately $460,014. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 51.39% of the company’s stock.

Venus Concept Stock Performance

VERO stock traded down $0.02 during midday trading on Friday, reaching $0.78. The company’s stock had a trading volume of 18,589 shares, compared to its average volume of 1,030,227. The firm has a market capitalization of $4.97 million, a price-to-earnings ratio of -0.12 and a beta of 0.58. Venus Concept has a 1 year low of $0.46 and a 1 year high of $2.44. The stock has a fifty day simple moving average of $0.72 and a two-hundred day simple moving average of $0.91.

Venus Concept (NASDAQ:VERO) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($1.68) EPS for the quarter. The firm had revenue of $17.48 million for the quarter. As a group, analysts forecast that Venus Concept will post -4.66 EPS for the current fiscal year.

About Venus Concept

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.